Skip to main content
OpenTrials
Completed

NCT Number: NCT06796530

High Intensity Exercise in Children With MCADD

Medium-chain acyl-CoA dehydrogenase deficiency (MCADD) is a rare genetic disorder affecting the body's ability to break down certain fats (β-oxidation) for energy, leading to symptoms like hypoketotic hypoglycaemia, jaundice, cardiomyopathy and seizures. responsible for the dehydrogenation step of fatty acids with chain lengths between 6 and 12 carbons as they undergo beta-oxidation in the mitochondria. Deficiency in MCAD can result in energy deficiency, the accumulation of acylcarnitine's and low serum carnitine concentrations.

The primary objective of the pilot study is to analyse the effects of high-intensity exercise (cardiopulmonary exercise testing (CPET) & high intensity circuit exercises ) on metabolic parameters and safety. This research is a pilot study comparing four patients with MCADD to four control subjects with the same characteristics. Blood samples are collected for analysis of substrate utilization.

Completed

Looking for future studies?

Notify Me

Key information

Age range

8 year–17 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Ghent University Hospital

Ghent, East Flanders, 9000, Belgium

About this study

The primary objective of the study is to analyse the effects of high-intensity exercise (CPET & high intensity circuit exercises) on metabolic parameters and safety. Since exercise is tested approximately two hours after a meal, we expect few symptoms, as fat metabolism is only minimally engaged at this intensity. Of interest could be the recovery from exercise, as fat metabolism is presumably activated during this phase.

Each MCADD-patient will attend two experimental visits. On the day of the first visit, the patient will arrive at UZ Gent after 1.5-hours following the meal. After 30 minutes, they will perform a cardiopulmonary exercise test (CPET) on a cycle ergometer. The standard CPET protocol that will be used is as follows: first, three minutes of cycling at a constant load (body weight (kg) / 2) in Watts), followed by a maximal exercise test (Ramp protocol: (body weight (kg) / 4) in Watts per minute). During the cycling test, gas exchange (spirometry) is measured, and an ECG is taken. If no symptoms are observed, the patient may return home. On the second test day, two hours before the test, a breakfast will be consumed. 1.5-hours following the meal, the patient will arrive at UZ Gent, where a heart monitor will be placed, and an intravenous line will be inserted. Following this, the patient will undergo a high-intensity exercise circuit. Blood samples will be taken before and after the exercise at various intervals: immediately, after 30 minutes, 1 hour, and 1.5-hours. Also, RER will be determined at each timepoint using indirect calorimetry. If no symptoms appear, the patient may return home. The patient will report symptoms for the 48 hours following the test. In the blood samples, measures of substrate utilization will be monitored: Glucose, lactate, acylcarnitine levels, free fatty acids (FFA). Also a marker of muscle damage will be assessed (creatine kinase). Additional measures include: anthropometric measurements, including weight and height, physical activity through the children physical activity questionnaire).

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 8-17y old
  • Control subjects matched by sex, age, and self reported Tanner stage.
  • All children: height and weight between P5-P95

Exclusion criteria

  • No daily medication use
  • No conditions other than MCADD that restrict sports participation or physiology (e.g., no heart diseases, diabetes).
  • < P5 or > P95 on the height-weight curve
  • No neuromotor developmental delay (e.g., delayed achievement of motor milestones)
  • No recent immobilization (<6 months)
  • No surgeries involving the musculoskeletal system

Treatment and study plan

cardiopulmonary exercise test (CPET)

Procedure

Participants undergo a CPET on a stationary bike, measuring gas exchange, ECG, and other parameters. The protocol includes 3 minutes of cycling at a constant load (body weight/2 in Watts), followed by a maximal effort test with an incremental load (Ramp protocol body weight (kg) / 4 in Watts per minute).

High-intensity circuit training

Procedure

The patients will undergo a 10-minute warm-up, followed by ~30 high intensity exercise circuit.

Primary outcomes

  1. glucose

    Time frame: From start of exercise until 1.5 hours post-exercise.

    Analysis of glucose in blood samples taken before, immediately after, and at intervals (30 minutes, 1 hour, and 1.5 hours) following high-intensity exercise.

Secondary outcomes

  1. Cardiorespiratory response during CPET

    Time frame: During CPET (approximately 30 minutes).

    Measurement of maximal oxygen uptake during the cardiopulmonary exercise test (CPET) on a stationary bike.

  2. Safety: Incidence of adverse events during and after exercise.

    Time frame: During and up to 48 hours post-exercise.

    Monitoring and recording of any symptoms, adverse events, or complications during exercise and the following 48 hours

  3. acylcarnitines

    Time frame: From the end of the exercise circuit until 1.5 hours post-exercise.

    Monitoring of acylcarnitines before and after high intensity exercise

Other outcomes

  1. creatine kinase

    Time frame: From the end of the exercise circuit until 1.5 hours post-exercise.

    Assessment of serum creatine kinase (CK) levels before and after exercise

  2. lactate

    Time frame: From the end of the exercise circuit until 1.5 hours post-exercise.

    Assessment of lactate levels before and after exercise

  3. Fat metabolism during recovery phase.

    Time frame: From the end of the exercise circuit until 1.5 hours post high intensity exercise.

    Monitoring of substrate utilization (including fat metabolism) through measurement of RER.

Sponsors and collaborators

Lead sponsor

University Hospital, Ghent

Other

Registry information

Official study title

Medium-Chain Acyl-Coa Dehydrogenase Deficiency (MCADD) and Exercise

Acronym: MCADD-EX

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jan 28, 2025
Registry last updated
Mar 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.